1. |
Hayashi H, Iihara H, Hirose C, Fukuda Y, Kitahora M, Kaito D, Yanase K, Endo J, Ohno Y, Suzuki A, Sugiyama T. Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer. Lung Cancer. 2019; 134: 1-6. |
---|---|
2. |
Iihara H, Shimokawa M, Gomyo T, Fujita Y, Yoshida T, Funaguchi N, Minato K, Kaito D, Osawa T, Yamada M, Hirose C, Suzuki A, Ohno Y. Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial. BMJ. 2019; 9(7): e028056. |
3. |
Mori H, Sakai C, Iwai M, Sasaki Y, Gomyo T, Toyoshi S, Kaito D, Yanase K, Ito F, Endo J, Funaguchi N, Ohno Y, Minatoguchi S. Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer. Respir Med Case Rep. 2019; 28: 100871. |
ATS American Thoracic Society International Conference (Dallas, Texas) 2019,5.17-22 | |
1. |
Gomyo T, Iihara H, Hayashi H, Endo J, Ito F, Yansase K, Kaito D, Sasaki Y, Sakai C, Fukuda Y, Hirose C, Sugiyama T, Suzuki A, Ohno Y. “Relationship Between Severity of Adverse Events of Afatinib and Its Pharmacokinetics and Pharmacogenomics for EGFR Mutation-Positive Non-Small Cell Lung Cancer.” |
---|